Erenumab for Prevention of Migraine
Article Sidebar
Main Article Content
Abstract
According to "The Prevalence and Burden of Migraine and Severe Headache in the United States: Updated Statistics From Government Health Surveillance Studies" Project (2015), headache or pain in the head (Migraine), found in all ages of patients, was the fourth most common cause of visits to the emergency department (ED) in 2009-2010. Besides, the National Health Interview Survey (NHIS) in 2012 reported that adults over the age of 18 having a migraine or severe headache accounted for 14.2% of the total US population, and this was found more in female than in male patients (19.1% and 9.0%, respectively). Migraine is a neurological disease that has dramatic effects on patients' lives. Currently, prophylaxis drugs used to prevent recurrence of acute migraine headaches have many limitations, and some of them also cause severe side-effects.
This article collects information about the development of a new drug with more targeted specificity. Erenumab, a novel for prevention of migraine, is an immunoglobulin G2 monoclonal antibody that binds and antagonizes the calcitonin gene-related peptide receptor (CGRP-R) – which is believed to play a critical role in migraine. Erenumab was approved by the US Food and Drug Administration (FDA) on May 2018. Erenumab can reduce the vasodilation and inflammation associated with the pathophysiology of migraines, which can decrease the number of days that patients experience migraines and decrease the use of acute migraine medication
Article Details
References
2. Mospan C, Mospan G, Byland E, Whitaker WB, Xiong L, Dunlap J, et al. Drug updates and approvals: 2018 in review. Nurse Pract. 2018;43(12):23-32.
3. Woottiwong B. Migraine headaches [Internet]. Nonthaburi: Center for Continuing Pharmaceutical Education. The Pharmacy Council of Thailand; 2017 [cited 2019 Jan 4]. Available from:
https://ccpe.pharmacycouncil.org/index.php?option=article_detail&subpage=article_detail&id=306
4. Jaiklom C, Ausavutmugkul T, Bunyapat N, Prasat Neurological Institute. Effect of pharmaceutical care in epileptic patients at Prasat Neurological Institute. J Dept Med Service. 2016;41(1):110-9.
5. Amgen Inc. AIMOVIG™ (erenumab-aooe) injection [Internet]. Thousand Oaks, CA: One Amgen Center Drive; 2018 [cited 2019 Jan 4] Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761077s000lbl.pdf
6. DrugBank. Erenumab [Internet]. 2018 [cited 2019 Jan 4]. Available from: https://www.drugbank.ca/drugs/DB14039
7. Micromedex. Erenumab-aooe [Internet]. 2018 [cited 2019 Jan 15]. Available from: https://www.micromedexsolutions.com
8. Ema.europa.eu [Internet]. Amsterdam: Aimovig; c1995-2019 [updated 2019 May 6; cited 2019 Jan 15]. Available from:
https://www.ema.europa.eu/en/documents/product-information/aimovig-epar-product-information_en.pdf
9. Raddant AC, Russo AF. Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation. Expert Rev Mol Med. 2011;13:e36.
10. Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377(22):2123-32.
11. Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38(6):1026-37.
12. Tepper S, Ashina M, Reuter U, Brandes JL, Dolezil D, Silberstein S, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425-34.